NOVN.SW CHMP opinion: Thursday, September 17, 2026
Variation type II · Rhapsido · Submission of the final report for study CLOU064A02105. This is a Phase 1, open-label, 3-group study to assess the effect of rabeprazole and omeprazole on the pharmacokinetics of remibrutinib in healthy participants.
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.